Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Clinical trial NCT03207256 · TERMINATED
Trial details
- NCT number
- NCT03207256
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-09
- Primary completion
- 2022-05-25
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.